CD4 and neoplasm: In 2008, a pilot clinical trial with anti-CTLA-4 (ipilimumab) treatment on 12 early UBC patients before radical cystectomy showed that the expression of inducible co-stimulator (ICOS) had increased significantly in CD4+ T-cell subpopulation from both tumor tissues and peripheral blood.